Full Press Release Details
Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Summit Therapeutics to Participate in Upcoming Investor Conferences
Oxford, UK, and Cambridge, MA, US, 4 September 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will participate in several upcoming investor conferences taking place in New York City.
9 September 2019 – Janney Healthcare Conference
10 September 2019 – H.C. Wainwright 21st Annual Global Investment Conference, presentation at 12:05pm EDT
23-24 September 2019 – Oppenheimer Fall Summit
A live webcast of the H.C. Wainwright presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. There will be no podium presentations at the Janney and Oppenheimer conferences.
About Summit Therapeutics
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking | ||
| Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
| Phil Walker / Dominic Wilson | ||
| MSL Group (US) | Tel: | +1 781 684 6557 |
| Jon Siegal | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Sue Stuart / Sukaina Virji | summit@consilium-comms.com | |
| Lindsey Neville |